Literature DB >> 3659072

Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine.

G Spignoli1, G Pepeu.   

Abstract

The effect of cognition-enhancing agents oxiracetam and aniracetam on scopolamine-induced amnesia and brain acetylcholine decrease was investigated in the rat. Acetylcholine levels were measured by means of a gas-chromatographic method. Scopolamine (0.63 mg/kg IP 60 min before training) prevented the acquisition of a passive avoidance conditioned response ("step through": retest 30 min after training) and brought about a 64, 56 and 42% decrease in acetylcholine level in the cortex, hippocampus and striatum respectively. Oxiracetam (50 and 100 mg/kg IP) administered 30 min before scopolamine reduced the scopolamine-induced amnesic effect and decrease in acetylcholine level in the cortex and hippocampus, but not in the striatum. Lower and higher doses of oxiracetam were ineffective. Aniracetam (100 mg/kg PO) also prevented scopolamine-induced amnesia but attenuated acetylcholine decrease in the hippocampus only. Aniracetam (300 mg PO) reduced acetylcholine decrease in the hippocampus but did not prevent scopolamine-amnesia. In conclusion, oxiracetam and aniracetam exert a stimulatory effect on specific central cholinergic pathways. However, a direct relationship between cognition-enhancing properties and cholinergic activation needs further confirmation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3659072     DOI: 10.1016/0091-3057(87)90353-4

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  18 in total

Review 1.  An hypothesis on the role of glucose in the mechanism of action of cognitive enhancers.

Authors:  G L Wenk
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 2.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat.

Authors:  M L Woolley; K A Waters; J E Gartlon; L P Lacroix; C Jennings; F Shaughnessy; A Ong; D J Pemberton; M H Harries; E Southam; D N C Jones; L A Dawson
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

4.  Effect of the nootropic drug oxiracetam on field potentials of rat hippocampal slices.

Authors:  A M Pugliese; R Corradetti; L Ballerini; G Pepeu
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

Review 5.  Age-related alteration of PKC, a key enzyme in memory processes: physiological and pathological examples.

Authors:  A Pascale; S Govoni; F Battaini
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

Review 6.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function.

Authors:  Santoshkumar Tota; Kashif Hanif; Pradeep Kumar Kamat; Abul Kalam Najmi; Chandishwar Nath
Journal:  Psychopharmacology (Berl)       Date:  2012-02-24       Impact factor: 4.530

8.  Oxiracetam antagonizes the disruptive effects of scopolamine on memory in the radial maze.

Authors:  M Magnani; O Pozzi; R Biagetti; S Banfi; L Dorigotti
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 9.  Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders.

Authors:  C R Lee; P Benfield
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

10.  Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock.

Authors:  J Itoh; T Nabeshima; T Kameyama
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.